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Abstract
Background & Aim: Nonalcoholic fatty liver disease (NAFLD) is the most common
chronic liver disease in both adult and children. Currently there are no reliable
methods to determine disease severity, monitor disease progression, or efficacy of
therapy, other than an invasive liver biopsy.
Design: Choline Deficient L-Amino Acid (CDAA) and high fat diets were used as
physiologically relevant mouse models of NAFLD. Circulating extracellular vesicles
were isolated, fully characterized by proteomics and molecular analyses and
compared to control groups. Liver-related microRNAs were isolated from purified
extracellular vesicles and liver specimens.
Results:We observed statistically significant differences in the level of extracellular
vesicles (EVs) in liver and blood between two control groups and NAFLD animals.
Time-course studies showed that EV levels increase early during disease
development and reflect changes in liver histolopathology. EV levels correlated with
hepatocyte cell death (r250.64, p,0.05), fibrosis (r250.66, p,0.05) and
pathological angiogenesis (r250.71, p,0.05). Extensive characterization of blood
EVs identified both microparticles (MPs) and exosomes (EXO) present in blood of
NAFLD animals. Proteomic analysis of blood EVs detected various differentially
expressed proteins in NAFLD versus control animals. Moreover, unsupervised
hierarchical clustering identified a signature that allowed for discrimination between
NAFLD and controls. Finally, the liver appears to be an important source of
circulating EVs in NAFLD animals as evidenced by the enrichment in blood with
miR-122 and 192 - two microRNAs previously described in chronic liver diseases,
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coupled with a corresponding decrease in expression of these microRNAs in the
liver.
Conclusions: These findings suggest a potential for using specific circulating EVs
as sensitive and specific biomarkers for the noninvasive diagnosis and monitoring
of NAFLD.
Introduction
Non-alcoholic Fatty Liver Disease (NAFLD) has become the most common form
of chronic liver disease in both children and adults, affecting up to 30% of the
American population [1, 2]. NAFLD encompasses a wide spectrum of conditions
associated with an over-accumulation of fat in the liver, ranging from hepatic
steatosis to steatohepatitis (NASH) and cirrhosis [3]. Hepatic steatosis is
characterized by an isolated accumulation of lipids in the liver and is generally
thought to follow a relatively benign, non-progressive clinical course [4]. NASH,
on the other hand, is a serious condition with about 5 to 25% of patients
progressing to fibrosis and cirrhosis with the associated complications of portal
hypertension, liver failure and hepatocellular carcinoma [3, 5]. Liver biopsy, an
invasive procedure associated with possible significant complications, presently
remains the only reliable method to differentiate hepatic steatosis from NASH
[6, 7] and monitor any response to therapeutic interventions. Therefore, there is
currently a significant interest in in developing non-invasive tests for this
condition [8].
Extracellular vesicles (EVs) are small membrane vehicles released from dying or
activated cells. There are two main populations of EVs, namely exosomes (EXO)
and microparticles (MPs), which differ in size, composition and mechanism of
generation. Exosomes are small, 30–100 nm in diameter, and are released by
exocytosis as a result of multivesicular bodies fusing with the plasma membrane.
MPs are small structures surrounded by a phospholipid bilayer and have a
diameter between 100–1000 nm. MPs are generated and released through a
controlled budding/blebbing of the plasma membrane. This process involves a
regulated sorting of bioactive molecules into the shed MP. Moreover, MPs feature
a flipping of phosphatidylserine from the inner to the outer membrane during
cellular activation or early apoptosis and they can be isolated by differential
ultracentrifugation and FACS analyses [9]. EVs are key cell-to-cell communicators
because they carry signatures from parenteral cells such as surface receptors,
proteins (membrane, cytosolic and nuclear), RNAs (including mRNAs and
microRNAs) and lipids [10–12]. EVs deliver these molecular packets of
information to other cells through an interaction with surface receptors or
internalization [13, 14]. Notably, released EVs do not only stay in the tissue of
origin, but also circulate in the blood stream. Indeed, recent studies from our
group and others have demonstrated that primary and immortalized hepatocytes
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are capable of producing and releasing the two main subtypes of EVs: exosomes
and MPs [15–18]. Moreover, we further demonstrated that EVs are formed and
released during the accumulation of lipotoxic lipids in hepatocytes, which is a key
mechanism of liver damage and disease progression in NAFLD [18, 19]. In vivo
studies in bile duct-ligated rats have found increased circulating MPs, while two
recent pilot studies in humans showed increased levels of inflammatory cell-
derived MPs in patients with NAFLD and in patients with alcohol and/or chronic
hepatitis C related cirrhosis [15, 20, 21]. Thus, in this study we examined whether
EVs are increased in liver and blood during experimental NAFLD. In order to
better understand whether EVs may be novel non-invasive biomarkers to monitor
liver damage in NAFLD we aimed to assess a detailed characterization of EV
populations released during experimental NAFLD development and the utility of
monitoring and quantifying EVs in blood as biomarkers of liver damage.
Materials and Methods
Animal studies
Male C57BL/6 wild type mice, 20 to 25 gm of body weight, 7 weeks old, were
placed on a Choline Deficient L-Amino Acid (CDAA) (Dyets, Bethlehem, PA,
USA) diet or on one of two control diets (Choline Supplemented L-Amino Acid,
(CSAA); and normal chow) for 4, 8 or 20 weeks. This diet (CDAA) has been
extensively shown to result in steatosis associated with significant inflammation
and progressive fibrosis, which is pathologically similar to human severe
steatohepatitis [22]. Additionally n56 mice were placed on a high fat diet (HF)
containing 45% kcal from fat, 18.8 kJ/g (Research Diets, New Brunswick, NJ,
USA) or normal chow diet for 12 weeks to investigate our hypothesis on a
different model of experimental NAFLD [23]. Mice were sacrificed and the liver
and blood were collected under anesthesia achieved by i.p. injecting with a 21G
needle, a mixture of 100 mg/Kg of Ketamine and 10 mg/Kg of Xylazine dissolved
in a 0.9% saline solution [24]. The studies were approved by the University of
California San Diego Institutional Animal Care and Use Committee and followed
the National Institutes of Health guidelines outlined in ‘‘Guide for the Care and
Use of Laboratory Animals’’.
Histopathology, immunohistochemistry and plasma assays
Plasma alanine aminotransferase (ALT) activity was measured by using a
commercial kit (Sekisui Diagnostics, LLC, Framingham, New York). Liver tissue
was fixed in 10% formalin. Specimens were routinely processed, embedded in
paraffin, sectioned at 10 mm and stained with hematoxylin and eosin (H&E).
Hepatic steatosis, inflammation and ballooning were assessed in NAFLD/NASH
and control mice by an experienced pathologist (Dr. Bettina G. Papouchado) in a
blinded fashion. Scoring analysis was based on NAFLD activity score (NAS) [25].
Immunohistochemistry for detection of pathological angiogenesis was performed
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using an anti-CD-31polyclonal rabbit antibody (1:25; Abcam, Cambridge, MA) as
previously described [18]. For detection of tissue collagen deposition, a Sirius red
(saturated picric acid containing 0.1% Direct Red 80 and 0.1% Fast Green FCF)
staining was performed. To detect cell death in paraffin-embedded liver specimens
the ApopTag peroxidase in situ apoptosis detection kit (Millipore, Billerica, MA,
USA) was used according to manufacturer’s instructions. Sirius red positive areas
and TUNEL-positive cells were analyzed in five random low-power views on each
slide using Image J Software (NIH). 10, 20 or 40X magnifications were used for
imaging.
Isolation of circulating extracellular vesicles
Circulating extracellular vesicles were isolated from fresh blood samples harvested
from CDAA, CSAA, HF and normal chow fed mice. Approximately 1 mL of
whole blood was collected in heparin-conditioned 1.5 mL tubes and centrifuged
at 1,200 g for 15 minutes in order to obtain platelet-poor plasma (PPP).
Supernatant containing EVs was centrifuged at 12,000 g for 12 minutes in order
to get the platelet-free plasma (PFP), as described previously [26]. To differentially
isolate microparticles and exosomes, PFP was additionally ultracentrifuged at
20,000 g for 30 minutes at 10 C˚ (SW41, Beckman, Indianapolis, IN, USA) to
pellet microparticles. The MP-free supernatant was transferred to a new tube and
ultracentrifuged at 100,000 g for 1 h at 10 C˚ to pellet exosomes. The size of MPs
and exosomes was determined by a Dynamic Light Scattering Zetasizer (Malvern,
Worcestershire, UK).
Flow cytometry
Circulating extracellular vesicle acquisition was performed by means of the BD
LSRII Flow Cytometer System (BD Biosciences, San Jose, CA, USA) and the data
were analyzed using FlowJo software (TreeStar Inc., Ashland, OR, USA). A
volume of 30 mL of PFP was filtered on a 0.22-mm filter (Millipore) and incubated
with 1 mM of Calcein AM (BD Biosciences, San Jose, CA, USA) in PBS for 1 h at
37 C˚. Calcein AM, a non-fluorescent marker that becomes fluorescent (emission
wavelength of 515 nm) upon cleavage by cytosolic esterases, stains only intact
extracellular vesicles and it is not reactive with cellular fragments. Standardization
of the protocol was achieved using 1 mm latex fluorescent beads (Sigma-Aldrich,
St Louis, MO, USA) and ultraviolet 2.5 mm flow cytometry alignment beads
(Invitrogen, Grand Island, NY, USA). Forward (FS) and side scatter (SS)
parameters were plotted on logarithmic scales to best cover a wide size range.
Single staining controls were used to check fluorescence compensation settings
and to set up positive regions. Lightning-link conjugation kit (Novus Biologicals,
Littleton, CO, USA) was used to generate phycoerythrin (PE)-conjugated anti-
mouse liver carboxylesterase monoclonal antibody (Abcam). Circulating EVs
isolated from mice fed with CSAA and CDAA diet for 20 weeks were double-
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labelled with Calcein AM and liver carboxylesterase to quantify liver-derived EVs
in the whole vesicle population.
Sucrose gradient
For the proteomics analysis, platelet-free plasma samples were purified on a 10–
70% sucrose gradient as previously described [27], with some modifications.
Approximately 2 mL of PFP isolated from CDAA- and CSAA-fed mice for 20
weeks were layered on top of the sucrose gradient in SW41 tubes (Beckman
Coulter Inc., Brea, CA, USA) and ultracentrifuged at 100,000 g for 18 h at 10 C˚.
Fractions comprised between 1.19 and 1.26 g/mL21 were collected, resuspended
in PBS and further ultracentrifuged at 100,000 rpm for 1 h at 10 C˚ to wash out
sucrose from EV preparation. For the EV characterization, the same fractions were
ultracentrifuged at 20,000 g for 30 min at 10 C˚ to pellet the microparticles. The
supernatant was transferred to a new tube and centrifuged at 100,000 g for 1 h at
10 C˚ to pellet exosomes. The resulting purified microparticles and exosomes were
resuspended in PBS and processed for western blot, FACS and dynamic light
scattering analyses.
Sample preparation for MS
Protein samples were diluted in TNE (50 mM Tris pH 8.0, 100 mM NaCl, 1 mM
EDTA) buffer. RapiGest SF reagent (Waters Corp.) was added to the mix to a final
concentration of 0.1% and samples were boiled for 5 min. TCEP (Tris (2-
carboxyethyl) phosphine) was added to 1 mM (final concentration) and the
samples were incubated at 37 C˚ for 30 min. Subsequently, the samples were
carboxymethylated with 0.5 mg/ml of iodoacetamide for 30 min at 37 C˚ followed
by neutralization with 2 mM TCEP (final concentration). Protein samples
prepared as above were digested with trypsin (trypsin:protein ratio –1:50)
overnight at 37 C˚. RapiGest was degraded and removed by treating the samples
with 250 mM HCl at 37 C˚ for 1 h followed by centrifugation at 14000 rpm for
30 min at 4 C˚. The soluble fraction was then added to a new tube and the peptides
were extracted and desalted using Aspire RP30 desalting columns (Thermo
Scientific).
LC-MS-MS analysis
Trypsin-digested peptides were analyzed by high pressure liquid chromatography
(HPLC) coupled with tandem mass spectroscopy (LC-MS/MS) [28]. The
nanospray ionization experiments were performed using a TripleTof 5600 hybrid
mass spectrometer (ABSCIEX) interfaced with nano-scale reverse-phase HPLC
(Tempo) using a 10 cm-100 micron ID glass capillary packed with 5-mm C18
ZorbaxTM beads (Agilent Technologies, Santa Clara, CA). Peptides were eluted
from the C18 column into the mass spectrometer using a linear gradient (5–60%)
of ACN (Acetonitrile) at a flow rate of 250 ml/min for 1 h. The buffers used to
create the ACN gradient were: Buffer A (98% H2O, 2% ACN, 0.2% formic acid,
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and 0.005% TFA) and Buffer B (100% ACN, 0.2% formic acid, and 0.005% TFA).
MS/MS data were acquired in a data-dependent manner in which the MS1 data
were acquired for 250 ms at m/z of 400 to 1250 Da and the MS/MS data were
acquired from m/z of 50 to 2,000 Da. For Independent data acquisition (IDA)
parameters MS1-TOF 250 milliseconds, followed by 50 MS2 events of 25
milliseconds each. The IDA criteria, over 200 counts threshold, charge state +2–
4 with 4 seconds exclusion. Finally, the collected data were analyzed using
MASCOT (Matrix Sciences) and Protein Pilot 4.0 (ABSCIEX) for peptide
identifications [29, 30]. The SEQUEST algorithm was used to match MS/MS
spectra to peptides in the sequence databases [31, 32]. Data of EV proteins isolated
from CDAA and CSAA-fed mice were normalized to those obtained from normal
chow-fed mice.
Electron microscopy
For transmission electron microscopy, extracellular vesicles were adhered to
100 mesh Formvar and carbon coated grids for 5 minutes at room temperature.
Grids were washed once with water, stained with 1% uranyl acetate (Ladd
Research Industries, Williston VT) for 1 minute, dried and viewed using a JEOL
1200 EXII transmission electron microscope. Images were captured using a Gatan
Orius 600 digital camera (Gatan, Pleasanton, CA). Liver samples were collected
from the CDAA-fed mice after a short liver perfusion with 10 mL of 4%
paraformaldehyde in 0.15 M sodium cacodylate buffer, pH 7.4 by using a 21 G
needle. Samples were immersed in modified Karnovsky’s fixative (2.5%
glutaraldehyde and 2% paraformaldehyde in 0.15 M sodium cacodylate buffer,
pH 7.4) for at least 4 hours, postfixed in 1% osmium tetroxide in 0.15 M
cacodylate buffer for 1 hour and stained en bloc in 3% uranyl acetate for 1 hour.
Samples were dehydrated in ethanol, embedded in Durcupan epoxy resin (Sigma-
Aldrich), sectioned at 50 to 60 nm on a Leica UCT ultramicrotome, and picked
up on Formvar and carbon-coated copper grids. Sections were stained with 3%
uranyl acetate for 5 minutes and Sato’s lead stain for 1 minute. Grids were viewed
using a JEOL 1200EX II (JEOL, Peabody, MA) transmission electron microscope
and photographed using a Gatan digital camera (Gatan, Pleasanton, CA).
Immunoprecipitation of miR-122 associated with Argonaute-2
(Ago2) complexes
Platelet-free plasma isolated from CDAA and CSAA-fed mice for 20 weeks was
centrifuged for 1 h at 30,000 rpm at 10 C˚ to pellet extracellular vesicles (EV). A
volume of 200 mL of vesicles-free supernatant was diluted in 200 mL (1:1) of PBS
solution and immunoprecipitated as detailed previously [33]. Amount of miR-
122 encapsulated in EVs and associated with Ago2 was determined by miRNeasy
Mini kit (QIAGEN). CDNA was synthesized using specific miRNA primers
(Applied Biosystems) in TaqMan microRNA Reverse Transcription kit (Applied
Biosystems). MiRNA abundance was detected with TaqMan probe (Applied
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Biosystems) on 7300 Real time PCR system (Applied Biosystems). The U6 snRNA
was used as an internal control.
Real-time PCR and miRNA expression
Liver samples were harvested from mice and homogenized. Total RNA was
isolated using RNeasy kit (Qiagen, Valencia, CA) and reverse transcribed by
iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer’s instruc-
tions. Quantitative Real time PCR was performed on a BioRad Cycler (Biorad,
Hercules, CA, USA) by using SYBRGreen real time PCR master mix
(Kapabiosystem, Woburn, MA, USA) according to the manufacturer’s instruc-
tions. The housekeeping gene 18S was used as an internal control. The PCR
primers used to amplify each gene are listed in Table S2. For isolation and
quantification of miR-122 and miR-192, platelet-free plasma was isolated from
CDAA-fed, high fat or control mice and incubated with 10 mg/mL of RNase
(Roche, Indianapolis, IN, USA) for 30 min at 37 C˚ to remove any RNAs adhering
to the external leaflet of circulating EVs. Circulating EVs were then ultracen-
trifuged at 100,000 g for 90 min at 10 C˚. Total encapsulated RNAs in EVs or in
liver specimens, including miRNAs, were isolated by miRNeasy Mini kit
(QIAGEN). CDNA was synthesized using specific miRNA primers (Applied
Biosystems) in TaqMan microRNA Reverse Transcription kit (Applied
Biosystems). MiRNA abundance was detected with TaqMan probe (Applied
Biosystems) on 7300 Real time PCR system (Applied Biosystems). The U6 snRNA
was used as an internal control and to normalize miR-122 and miR-192
expression.
Western blot analysis
Extracellular vesicles were isolated from blood samples as described in the ‘MPs
isolation and purification’ paragraph. Approximatively 10 mg of EV protein
lysates were solubilized in Laemli buffer, resolved by a 4–20% Criterion Tris-HCl
gel electrophoresis system(Biorad, Hercules, CA, USA) and transferred to a
0.2 mm nitrocellulose membrane (Biorad, Hercules, CA, USA). Primary rabbit
polyclonal antibody anti-mouse Vanin-1 (1:500; Proteintech, Chicago, IL, USA),
Cd63, Cd81, ASGPR1 (1:1000; Genetex, Irvine, CA, USA) and Icam-1 (1:1000;
Abnova, Taipei city, Taiwan) were incubated overnight at 4 C˚. Proteins were
visualized by Supersignal West Pico chemiluminescence substrate (Pierce
biotechnology, Rockford, IL, USA) and quantified by ImageJ software.
Statistical analysis
All data were expressed as the mean¡ SD unless otherwise indicated. Differences
between three or more groups were compared by a nonparametric Kruskal-Wallis
ANOVA test. If a significant effect was detected, post-hoc pair-wise comparisons
were performed using Mann-Whitney tests with Bonferroni correction.
Differences between two groups were compared by a two-sided Student’s t-test if
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the data were normal or a Mann-Whitney test if the data deviated from the
normal distribution. Differences were considered to be statistically significant at
P,0.05. Spearman’s correlation coefficient was calculated for the correlation
analyses and an r2 value higher than 0.7 was considered a strong correlation. All
statistical analyses were performed using GraphPad Prism 4.0c (La Jolla, CA,
USA) or R v3.0.2 (www.r-project.org).
Results
Diet-induced NAFLD promotes changes in the levels of EVs that
are early markers of disease severity and reflect changes in liver
histopathology
To investigate whether EVs are produced and released in NAFLD, we placed
C57BL/6 mice on a Choline Deficient L-Amino Acid (CDAA) or one of two
control diets (CSAA or normal chow). We observed that mice fed with the CDAA
diet developed significant macro-vesicular steatosis, marked inflammation, cell
death, pathological angiogenesis and fibrosis (Fig. 1A–B). By employing electron
microscopy we were able to identify a large presence of EVs in both liver
specimens and blood of NAFLD mice (Fig. 1C–D). Importantly, we observed that
EVs were predominantly detected between the hepatocyte villi and the sinusoid
wall (Fig. 1D). Additionally, FACS analysis identified a marked increase of
Calcein-positive EVs in blood isolated from CDAA fed mice compared to CSAA
and chow fed mice (Fig. 1E). Our findings of increased levels of circulating EVs in
mice with established severe NAFLD led us to further examine the potential role
of these vesicles as noninvasive monitoring tools of disease progression over time
and pathohistological severity. In order to address these questions, male C57BL/
6 mice were placed on the CDAA, CSAA or a regular chow diet for 4, 8 or 20
weeks. These time points have been shown to be associated with early, mild and
established NAFLD, respectively [22]. We observed that the increase in circulating
EVs isolated from platelet-free plasma was time-dependent. Determination of
liver fibrosis, cell death and pathological angiogenesis were further assessed
respectively by Sirius red staining for collagen deposition, TUNEL staining and
immunostaining for CD-31, a marker of endothelial cells. Mice placed on the
CDAA diet for 4 weeks showed early outcomes of liver injury, mice on the CDAA
diet for 8 weeks developed mild liver fibrosis, angiogenesis and cell death, while
mice on the CDAA diet for 20 weeks developed severe cell death, hepatic fibrosis
and pathological angiogenesis (Fig. 2A). These findings were also confirmed by
the histopathological analysis of NAFLD Activity Score (Fig. 2B), level of plasma
alanine aminotransferase (ALT) (Fig. 2C) and by the analysis of the transcripts for
pro-fibrogenic (a-Smooth Muscle Actin, CollagenIa1, Connective Tissue Growth
Factor) and pro-angiogenic genes (Vascular Endothelial Growth Factor-A,
CD126, Fibroblast Growth Factor-b) (Fig. 2D), which indicated a time-dependent
progression of all the main features of liver injury associated with NAFLD. FACS
analysis showed that the number of circulating EVs increased over time and
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became significantly higher by 8 weeks on the CDAA diet, a time point associated
with progressive changes from mild NAFLD (Fig. 2E). Indeed, Spearman
correlation analyses showed a significant correlation with EV level and ratio of
dead cells (r250.64, p,0.05), extent of liver fibrosis (r250.66, p,0.05) and
pathological angiogenesis (r250.71, p,0.05) (Fig. 2F). These findings suggest that
blood EVs are released by damaged or stressed hepatic cells during NAFLD
development in a time-dependent manner and their levels strongly correlate with
the extent of liver damage.
Circulating EVs in blood from NAFLD animals are predominantly
MPs and have a distinct antigenic composition
The findings of increased blood EVs in NAFLD as early markers of liver injury in
this condition led us to further explore the characteristics of these EVs. We next
performed a series of studies, including dynamic light scattering analysis and
FACS analysis, which identified two populations of extracellular vesicles released
in circulation during NAFLD development: microparticles (MP) and exosomes
(EXO) (Fig. 3). Indeed, analysis of EV size identified two distinct peaks, a large
predominant peak that corresponded to EVs with a diameter between 100 and
1,000 nm (mean 630 nm) consistent with the size previously reported for MPs
[21], and a second small peak of EVs with a diameter between 30 and 100 nm
(mean 100 nm) consistent with the size previously reported for exosomes [34, 35]
(Fig. 3A). In order to confirm the presence of EXO and MP in the whole
population of purified circulating extracellular vesicles isolated from the CDAA-
fed mice for 20 weeks, we performed western blot analyses for some exosomal
markers (Cd63, Cd81, Icam1), MP markers (AnnexinV and Vanin-1 (VNN1) -
the latter of which has recently been identified as a novel surface ectoenzyme
present in MPs released by stressed hepatocytes [18]), and for the hepatocyte-
specific asialoglycoprotein-receptor (ASGPR1), which was recently reported in
MPs released during post-ischemic reperfusion [36] (Fig. 3B). The presence of
circulating MPs was further confirmed by transmission electron microscopy (
Fig. 3C) and flow cytometry analysis of AnnexinV positive MPs in plasma of
NAFLD mice (Fig. 3D).
To determine whether the EV population present in blood from NAFLD
animals could be profiled based on the antigenic composition, we next focused on
the characterization of the antigenic composition of blood EVs in NASH. Indeed,
Figure 1. CDAA resembles the histopathological features of human NASH. (A) Liver specimens from wild type C57BL/6 mice (n512) fed with the
CDAA (CD), CSAA (CS) or chow diet for 20 weeks, were used for assessing liver damage (Hematoxylin & eosin staining, H&E), fibrosis by detecting the
collagen deposition (Sirius red staining), cell death (TUNEL staining) and pathological angiogenesis (CD31 staining). (B) Analysis of the expression of the
transcripts for VEGF-A, FGF-b, CD126 (VE-cadherin), Collagen type-I, a-smooth muscle actin (a-SMA) and CTGF, assessed by quantitative real-time PCR.
The housekeeping gene 18S was used as internal control. (C) Representative TEM microphotograph of circulating EVs isolated from CDAA-fed mice for 20
weeks. (D) Representative microphotograph of hepatic extracellular vesicles (EV, red circle) in the space of Disse (DS). Hepatocyte (H), (Ld) lipid droplet,
(m) microvilli. (E) Flow cytometry analysis (Whisker plot and dot plot) of circulating Calcein+ extracellular vesicles per mL of platelet-free plasma isolated from
CDAA (CD, n512), CSAA (CS, n512) or chow diet fed mice (n512) for 20 weeks. Values represent mean ¡ SD. *P,0.05, **P,0.005, ***P,0.0005,
Kruskal-Wallis test with post-hoc Mann-Whitney test and Bonferroni correction.
doi:10.1371/journal.pone.0113651.g001
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Figure 2. Release of circulating extracellular vesicles is time-dependent and correlates with the histopathological features of NASH. C57BL/6 mice
(n58–12) were fed with CDAA (CD) or chow diet for 4 weeks, 8 weeks or 20 weeks to mimic an early stage, mild stage or severe stage of NAFLD,
respectively. (A) Representative microphotographs of hematoxylin & eosin staining, collagen fibers deposition (Sirius red staining), cell death (Tunel
Blood Extracellular Vesicles in Chronic Liver Disease
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staining) and endothelial cells (CD31 immunostaining) in liver specimens harvested from mice fed a chow or CDAA diet for 4, 8 or 20 weeks. (B) H&E liver
specimens were analyzed in a blinded way for steatosis, inflammation and ballooning and NAS score was determined in mice fed with CDAA diet for 4, 8 or
20 wks or with control diets (chow or CSAA, *data shown in Fig. 1). (C) Plasma alanine aminotransferase (ALT). (D) qPCR of the pro-fibrogenic markers a-
SMA, Collagen-Ia1 and connective tissue growth factor (CTGF) and pro-angiogenic markers VEGF-A, FGF-b and VE-Cadherin (CD126) in chow or CDAA
fed mice for 4, 8 or 20 weeks. Mean values were normalized to 18S housekeeping gene. (E) Whisker plot of flow cytometry analysis of Calcein-FITC-positive
extracellular vesicles isolated from platelet-free plasma of chow or CDAA fed mice for 4, 8 or 20 weeks. (F) Spearman correlations between circulating level
of extracellular vesicles and cell death (TUNEL positive cells), hepatic fibrosis or endothelial cells (CD31-positive cells) in mice fed with chow or CDAA diet
for 4, 8 or 20 weeks. *P,0.05, **P,0.005, ***P,0.0005, Kruskal-Wallis test with post-hoc Mann-Whitney test and Bonferroni correction.
doi:10.1371/journal.pone.0113651.g002
Figure 3. Characterization of circulating extracellular vesicles (EV) in a diet-induced NASH model. (A) Dynamic light scattering analysis was
performed to determine the size of EVs isolated from the platelet-free plasma of CDAA-fed mice for 20 weeks. The graph shows a predominant peak of big
vesicles (mean 630 nm) corresponding to microparticles and a peak of smaller vesicles (mean 100 nm), corresponding to exosomes. (B) Exosomes (EXO)
and microparticles (MP) were separated from the whole EV population and markers of EXO (Cd63, Cd81, ICAM-1), MP (Vanin-1 and Annexin V) and the
hepatocyte-specific asialoglycoprotein-receptor (ASGPR1) were identified by western blot analysis. (C) Representative TEM macro photograph of
circulating EVs isolated from platelet-free plasma of CDAA-fed mice for 20 weeks. (D) Flow cytometry analysis of circulating AnnexinV+ microparticles per
mL of platelet-free plasma isolated from CDAA (CD), CSAA (CS) or chow diet fed mice for 20 weeks. *P,0.05, **P,0.005, ***P,0.0005, Kruskal-Wallis test
with post-hoc Mann-Whitney test and Bonferroni correction.
doi:10.1371/journal.pone.0113651.g003
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in order to identify potential protein targets present in blood EVs during NASH
development, we performed a proteomic analysis of purified blood EVs. For these
studies we obtained EVs from platelet-free plasma collected from mice fed the
CDAA or one of two control diets (CSAA and normal chow) for 20 weeks. We
then purified the EVs using sucrose gradient ultracentrifugation (Fig. S1) and,
lastly, we ascertained the EV proteome by LC-MS/MS analysis. Importantly, the
proteome of blood EVs isolated from CDAA mice differed from that of control
mice (Table S1). Table 1 lists all unique proteins identified in three independent
preparations of blood extracellular vesicles isolated from CDAA-fed mice.
Based on our proteomics analysis we found that several proteins were present in
all three groups, but a significant number of proteins were present only in EVs
isolated from CDAA-fed mice for 20 weeks (Fig. 4A). Additionally we observed
that EVs isolated from CDAA-fed mice carry more proteins involved in NASH-
associated outcomes such as cell death and stress and angiogenesis when
compared with EVs from mice fed with CSAA or chow diet (Fig. 4A). In order to
investigate whether the protein profile of blood EVs could be used to develop a
signature that aids in discriminating NAFLD animals from controls, the total
protein abundance for 158 targets were measured from 3 samples (different
repeats from 3 groups of n54 mice) from the CSAA and CDAA diet groups and
then normalized to the measurement from 12 normal chow mice. We then
compared the abundance of each protein between the CDAA and CSAA group
with the non-parametric two sample Wilcoxon (Mann-Whitney) test. 25 proteins
with p-value ,0.15 were considered candidate proteins for altered abundance.
These 25 proteins were all up-regulated in CDAA diet mice (Table 2). The
heatmap and dendrogram based on these 25 proteins show that the CDAA mice
are clearly separated, and therefore distinct, from the CSAA mice (Fig. 4B).
Findings show that within the most abundant proteins expressed in EVs isolated
from CDAA-fed mice some are hepatocyte-specific and involved in one or more
NAFLD-related outcomes, such as cell death, inflammation and pathological
angiogenesis.
Proteins identified in circulating EVs from CDAA fed mice for 20 weeks, could
be assigned to Genome Ontology (GO) categories which are defined by the GO
Consortium [37]. Based on the GO analysis of the newly discovered proteins,
blood EVs carry cytosolic, extracellular, plasma membrane, and nuclear proteins.
We found that some functional activities of oxidoreductase, hydrolase,
endopeptidase inhibitors, signal transducers and lipid binding proteins were
abundantly expressed in EVs, indicating that these activities might be of
important relevance regarding the potential effect of the circulating EVs on the
target cells or tissue (Fig. 4C). Moreover, the analysis identified a significant
number of proteins involved particularly in inflammation and immunity, cell
death, angiogenesis and cell adhesion, which represent all clinically-relevant
features of NASH (Fig. 4D). These results suggest that circulating EVs carry a
variety of different proteins, different in molecular function and biological
processes that reflect the pathological progression of NASH.
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Table 1. Protein identified by LC-MS/MS in circulating extracellular vesicles isolated from CDAA-induced NASH mice.
Gene symbol Gene ID Protein Description
Peptides
(95%) a % Cov b SpC c
Cytoskeletal remo-
delling/vesiculation
KRT6A 16687 Keratin, 6A, type II 20 47.87 47
ACT 11459 Actin 6 23.47 34
ACTG1 11465 Actin, gamma, 1 6 23.47 19
ADD2 11519 Beta-adducin 1 4.69 1
JUP 16480 Desmoplakin 1 0.31 1
PLAK 16480 Junction plakoglobin 4 8.32 6
KRT5 110308 Keratin 5 22 34.48 46
DMTN 13829 Dematin 1 3.13 2
KRT7 110310 Keratin 7, type II 2 10.72 21
VCP 269523 Transitional endoplasmic reticulum ATPase 3 6.7 3
SPTB 20742 Spectrin beta 1 27 21.08 46
SPTA1 20739 Spectrin alpha chain 32 24.8 65
KRT77 406220 Keratin 77 4 18.18 24
MPP1 17524 Membrane protein, palmitoylated 2 12.61 3
KRT17 16667 Keratin 17, type I 10 39.26 26
KRT25 70810 Keratin 25, type I 1 12.44 11
EPB41 269587 Erythrocyte protein band 4.1 6 12.89 8
GYPA 14934 Glycophorin A 1 18.45 1
LRG1 76905 Leucine-rich HEV glycoprotein 1 4.09 1
KRT1 16678 Keratin 1, type II 5 13.97 63
KRT2 16681 Keratin 2, type II 9 22.49 24
KRT73 223915 Keratin 73, type II 6 22.08 21
KRT10 16661 Keratin 10 7 12.11 100
NEST 18008 Nestin 1 2 2
KRT6B 16688 Keratin 6B, type II 5 6.01 26
KRT42 68239 Keratin 42, type I 4 8 8
Signalling/
Chaperone/
Transcription
regulation
PRDX2 21672 Peroxiredoxin-2 2 9.59 3
ZNF521 22696 Zinc finger protein 521 isoform 1 1 2.74 2
REFBP2 56009 RNA and export factor-binding protein 2 1 15.14 2
APOA1 11806 Apolipoprotein A–I 10 37.88 30
VWF 22371 von Willebrand factor 2 0.81 2
AQP1 11826 Aquaporin-1 2 10.78 7
ECM1 13601 Extracellular matrix protein 1 1 10.55 3
STOML3 13830 Stomatin 1 4.06 1
BACH1 12013 BTB and CNC homology 1 1 5.82 1
ATM 11920 Serine-protein kinase ATM 2 4.69 2
GABRA5 110886 Gamma-aminobutyric acid receptor subunit
alpha-5
1 3.35 1
LGALS3BP 16854 Galectin-3-binding protein 1 4.67 2
MVP 78388 Major vault protein 1 1.04 1
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Table 1. Cont.
Gene symbol Gene ID Protein Description
Peptides
(95%) a % Cov b SpC c
TSKU 244152 Tsukushi 1 9.605 1
TF 22041 Serotransferrin 48 58.82 323
PRDX2 21672 Peroxiredoxin-2 6 31.82 14
HMGA1 15361 High mobility group AT-hook 1 1 23.36 1
UBC 22190 Ubc protein 1 19.24 3
CHRNA10 504186 Cholinergic receptor, nicotinic, alpha polypep-
tide 10
1 2.01 1
ASAP2 211914 Arf-GAP with SH3, PH domains, ANK repeat 2 1 0.82 3
PRDX1 18477 Peroxiredoxin-1 2 14.06 4
PRDX4 53381 Peroxiredoxin-4 1 3.49 2
Enzymes/Metabolic
processes
FABP5 16592 Fatty acid binding protein 5 1 6.66 1
ADIPOQ 11450 Adiponectin 2 8.9 4
ALDOA 11674 Fructose-bisphosphate aldolase 1 6.31 1
APOA2 11807 Apolipoprotein A-II 8 71.57 25
HBB-A1 15122 Alpha-globin 1 8 39.44 300
ORM1 18406 Alpha-1-acid glycoprotein 1 1 4.34 7
SERPIN-1A 20700 Alpha-1-antitrypsin 1–1 (Serpin 1A) 6 13.56 21
SERPIN-1B 20701 Alpha-1-antitrypsin 1–2 (Serpin 1B) 6 13.56 21
SERPIN-1C 20702 Alpha-1-antitrypsin 1–3 (Serpin 1C) 6 13.35 22
SERPIN-1D 20703 Alpha-1-antitrypsin 1–4 (Serpin 1D) 5 11.38 20
SERPIN-1G 18787 Serine protease inhibitor G1 5 26.19 28
SERPIN-3A 20714 Serine protease inhibitor A3A 2 15.55 3
SERPIN-2F 18816 Alpha-1-antitrypsin-related protein 2 8.14 5
APOA4 11808 Apolipoprotein A-IV 1 4.55 1
APOE 11816 Apolipoprotein E 1 7.39 1
EPB42 13828 Erythrocyte protein band 4.2 6 12.47 10
FTL1 14319 Ferritin 1 16.39 1
GLUL 14645 Glutamine synthetase 4 14.48 6
GPX3 14778 Glutathione peroxidase 3 3 22.12 3
HP 15439 Haptoglobin 13 46.11 45
ALDH1A1 11668 Aldehyde dehydrogenase family 1 3 21.36 12
GAPDH 14433 Glyceraldehyde-3-phosphate dehydrogenase 2 15.62 3
HSPA1L 15511 Heat shock 70 kDa protein 1 1 7.95 1
HPX 15458 Hemopexin 16 49.78 52
PON1 18979 Serum paraoxonase/arylesterase 1 12 33.21 46
COLEC11 71693 Collectin-11 isoform II 1 8.27 1
PZP 11287 Pregnancy zone protein 153 60.2 253
MGAM 232714 Maltase-glucoamylase 2 3.83 2
ALDH1L1 107747 Cytosolic 10-formyltetrahydrofolate dehydro-
genase
2 14.26 4
MUG1 17836 Murinoglobulin-1 8 8.4 23
NUB1 53312 Nedd8 ultimate buster-1 1 2.93 1
PSMA1 19165 Proteasome subunit alpha type 1 2 14.83 3
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Table 1. Cont.
Gene symbol Gene ID Protein Description
Peptides
(95%) a % Cov b SpC c
PSMA3 19167 Proteasome subunit alpha type 3 2 17.09 9
PSMA4 26441 Proteasome subunit alpha type 4 1 10.34 5
PSMA6 19171 Proteasome subunit beta type 4 23.58 10
PSMB1 19170 Proteasome subunit beta type 1 4 37.08 14
PSMB6 19175 Proteasome subunit beta type 6 4 25.74 8
PSMB7 19177 Proteasome subunit beta type 7 1 20.58 4
HGD 15233 Homogentisate 1, 2-dioxygenase 3 21.8 4
LAP3 66988 Leucine aminopeptidase 3 2 30.83 3
RBP4 19662 Retinol binding protein 4, plasma 1 4.97 3
GC 14473 Vitamin D-binding protein 1 1.89 1
APCS 20219 Serum amyloid P-component 1 14.73 2
DNPEP 13437 Aspartyl aminopeptidase 3 7.02 5
DUSP9 75590 Dual specificity protein phosphatase 1 7.74 1
CANT1 76025 Calcium activated nucleotidase 1 1 3.18 2
CPB2 56373 Carboxypeptidase B2 2 3.79 1
CPN1 93721 Carboxypeptidase N, polypeptide 1 3 14.88 9
CPN2 71756 Carboxypeptidase N, polypeptide 2 2 12.98 9
CPB2 56373 Carboxypeptidase B2 2 3.79 1
GGTA1 14594 N-acetyllactosaminide alpha-1,3-galactosyl-
transferase
3 38.62 23
GPLD1 14756 Glycosylphosphatidylinositol specific phospholi-
pase D1
4 11.4 11
H6PD 14381 Hexose-6-phosphate dehydrogenase 1 2 1
UBE4B 63958 Ubiquitination factor E4B 1 1.87 2
ALB 11657 Albumin 114 70.07 7986
SLC4a3 20533 Band 3 anion transport protein 8 13.78 57
SERPIN-K3 20714 Serine protease inhibitor A3K 3 13.64 3
TTR 22139 Transthyretin 1 19.05 4
CP 12870 Ceruloplasmin 11 15.75 25
CES1c 13884 Liver carboxylesterase 1 4 17.51 10
OXR1 170719 Oxidation resistance protein 1 1 1.27 2
Fibrinolysis/
Coagulation
A2M 232345 Alpha-2-Macroglobulin 984 81.15 12620
KNG1 16644 Kininogen-1 2 4.37 4
KLK1 16612 Kallikrein B 4 21.94 11
F2 14061 Coagulation factor II 2 6.63 5
F13a1 74145 Coagulation factor XIII, A1 subunit 1 14.07 1
SERPIN-C1 11905 Antithrombin (Serpin C1) 2 11.4 5
PLAU 18787 Plasminogen 4 11.82 11
FGB 110135 Fibrinogen, B beta polypeptide 9 24.95 18
FGA 14161 Fibrinogen, A alpha polypeptide 5 16.7 14
FGG 14188 Fibrinogen, gamma polypeptide 34 51.38 134
SERPIN-G1 12258 Plasma protease C1 inhibitor (Serpin-G1) 5 16.43 24
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Table 1. Cont.
Gene symbol Gene ID Protein Description
Peptides
(95%) a % Cov b SpC c
Complement system/
Immunity
AHSG 11625 Alpha-2-HS-glycoprotein 2 24.06 4
ANK1 17733 Ankyrin 1 18 20.61 36
C1rA 50909 Complement C1r, subcomponent A 16 34.51 62
C1qA 12259 Complement C1q, subcomponent subunit A 8 40.41 40
C1qB 12260 Complement C1q subcomponent subunit B 10 25.69 64
C1qC 12262 Complement C1q subcomponent subunit C 7 30.49 56
C1qbp 12261 Complement C1q subcomponent binding pro-
tein
9 29.65 45
C1s 50908 Complement C1s subcomponent A 22 37.75 84
C3 12266 Complement C3 37 33.61 102
C4 12268 Complement C4 27 22.6 13
C5 15139 Complement C5 16 21.49 49
C8c 69379 Complement C8 polypeptide gamma 2 28.71 5
C9 12279 Complement C9 1 3.38 1
CD47 16423 Leukocyte surface antigen CD47 1 7.59 1
IgJ 16033 Immunoglobulin J chain 10 44.65 80
Igk 14972 Immunoglobulin k chain 1 10.32 7
Igc1 111507 Immunoglobulin c chain 1 2 30.26 9
Igc2b 111507 Immunoglobulin c chain 2b 2 10.21 11
FCN1 14133 Ficolin-1 1 2.69 2
MASP2 17174 Mannan-binding lectin serine protease 1 2 6.95 4
MBL1 17194 Mannose-binding lectin-1 3 15.16 13
PIGR 18703 Polymeric immunoglobulin receptor 7 14.4 13
CAMP 12796 Cathelin-related antimicrobial peptide 2 23.91 4
CRP 12944 C-reactive protein 8 33.78 24
Apoptosis CTSD 13033 Cathepsin-D 1 7.86 1
GSN 227753 Gelsolin 4 26.41 7
CRYAB 12955 Crystallin, alpha B 4 27.43 8
CLU 12759 Clusterin 3 14.73 7
CD5L 11801 CD5 antigen-like 16 41.76 81
Angiogenesis/Cell
adhesion/migration
RETNLG 57262 Myeloid cysteine-rich protein 7 34.19 21
IAP 16423 Leukocyte surface antigen CD47 1 7.59 1
DSG1A 13510 Desmoglein 1 alpha 1 1.22 4
SHC1 20416 SHC-transforming protein 1 1 2.85 1
DSG1B 225256 Desmoglein 1 beta 1 1.22 1
ANXA2 12306 Annexin A2 3 12.98 3
FN1 14268 Fibronectin 12 12.43 27
HRG 94175 Histidine-rich glycoprotein 2 6.71 2
VTN 22370 Vitronectin 5 17.15 15
a - Significant MS/MS number of peptides identified in blood EVs from CDAA-fed mice.
b - Significant MS/MS absolute % of coverage calculated in blood EV from CDAA-fed mice.
c - Significant MS/MS spectral counts identified in blood EVs from CDAA-fed mice.
doi:10.1371/journal.pone.0113651.t001
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Circulating EVs from NAFLD animals contain liver-related
microRNAs
Various recent reports have provided evidence that EVs contain non-coding
microRNAs from the cell of origin as part of their cargo and the presence of
specific microRNAs can be used to identify the cell of origin [38, 39]. Moreover,
we have recently demonstrated that hepatocytes release large quantities of EVs
when exposed to lipotoxic fatty acids that have been shown to be important
mediators of liver damage during NAFLD [40]. Based on these concepts we tested
the hypothesis that hepatocytes might be an important source of circulating EVs
Figure 4. Overview on proteome changes of circulating extracellular vesicles in diet-induced NASH or control mice. (A) Venn diagrams depicting
the total number of proteins and the number of proteins involved in cell death, stress and angiogenesis in EVs isolated from CDAA, CSAA or chow fed mice.
(B) Heatmap and dendrogram based on log2 of normalized spectral counts for proteins elevated in EVs isolated from CDAA (n53, CD) compared to CSAA
(n53, CS). Protein expression levels are color coded, showing a stronger and lower expression in green and red, respectively. Functional and molecular
grouping of proteins identified in EVs isolated from CDAA-fed mice for 20 weeks. By using annotations derived from the Gene Ontology database, proteins
have been organized based on (C) molecular function and (D) biological process.
doi:10.1371/journal.pone.0113651.g004
Table 2. A Nonparametric two-sample Wilcoxon test was performed in order to obtain a list of the most alternated proteins in EVs isolated from CDAA-fed
mice for 20 weeks compared to EVs isolated from CSAA-fed mice.
Gene ID Coverage (%) Abbreviation Description Log2 ratio W-test
20700 13.56 SERPIN-1A Alpha-1-antitrypsin 1–1 (Serpin 1A) 9.19 0.064
20701 13.56 SERPIN-1B Alpha-1-antitrypsin 1–2 (Serpin 1B) 5.31 0.077
20702 13.35 SERPIN-1C Alpha-1-antitrypsin 1–3 (Serpin 1C) 5.61 0.077
20703 11.38 SERPIN-1D Alpha-1-antitrypsin 1–4 (Serpin 1D) 5.54 0.077
15439 46.11 HP Haptoglobin 4.75 0.077
15458 49.78 HPX Hemopexin 4.61 0.077
11801 41.76 CD5L CD5 antigen-like 10.56 0.064
18406 4.34 ORM1 Alpha-1-acid glycoprotein 1 3.87 0.077
12759 14.73 CLU Clusterin 4.93 0.077
11625 24.06 AHSG Alpha-2-HS-glycoprotein 6.84 0.064
13437 7.02 DNPEP Aspartyl aminopeptidase 6.39 0.064
16644 4.37 KNG1 Kininogen-1 5.40 0.077
14133 2.69 FCN1 Ficolin-1 5.43 0.064
94175 6.71 HRG Histidine-rich glycoprotein 6.36 0.064
76905 4.09 LRG1 Leucine-rich HEV glycoprotein 6.42 0.064
11808 4.55 APOA4 Apolipoprotein A-IV 5.76 0.064
22139 19.05 TTR Transthyretin 9.79 0.064
12944 33.78 CRP C-reactive protein 9.34 0.064
12266 33.61 C3 Complement C3 4.85 0.116
17194 15.16 MBL1 Mannose-binding lectin-1 5.21 0.077
14268 12.43 FN1 Fibronectin 7.53 0.077
12870 15.75 CP Ceruloplasmin 8.48 0.064
17836 8.4 MUG1 Murinoglobulin-1 9.32 0.064
14161 16.7 FGA Fibrinogen, A alpha polypeptide 5.66 0.116
110135 24.95 FGB Fibrinogen, B beta polypeptide 6.30 0.077
doi:10.1371/journal.pone.0113651.t002
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in NAFLD animals. To test this hypothesis, we measured the level of miR-122 and
miR-192, two microRNAs abundant in hepatocytes [41–43], in blood EVs from
the CDAA treated and control mice. Indeed, we found that miR-122 and miR-192
levels in circulating EVs were significantly elevated in those isolated from CDAA-
fed mice compared to those from mice on the control diet (Fig. 5A). As a
consequence, and consistent to what has been recently reported in patients with
severe NAFLD or NASH [44], miR-122 and miR-192 levels decreased in the livers
of CDAA-fed mice for 20 weeks, compared to livers of mice fed with the control
diets (Fig. 5B). Additionally, the amount of liver carboxylesterase (CES1) and
hepatocyte-specific asialoglycoprotein-receptor (ASGPR1) positive EVs was
significantly higher in CDAA-fed mice compared to mice fed with the control diet
(1.65% vs. 9.59%) (Fig. 5C–D). While in healthy individuals, miR-122 has been
shown to circulate almost exclusively in a non-membrane bound form associated
with a specific protein, Argonaute2 (Ago2), while a recent report demonstrated
that in NAFLD patients the majority of serum miR-122 circulates in Ago2-free
forms [33]. Based on these findings and our results, we next tested the hypothesis
that in experimental NASH miR-122 is primarily encapsulated in EVs. We
therefore measured the level of miR-122 in the EV fraction and in the Ago2-
linked fraction. We observed that miR-122 was mainly encapsulated in EVs in
CDAA-fed mice for 20 weeks while it was primarily associated with Ago2 protein
in mice fed with the control diet, where the presence of EVs is very limited (
Fig. 5E). Furthermore, the levels of these two microRNAs increased in EVs from
NAFLD animals over time (Fig. 5F). These findings, in conjunction with the
findings of decreased levels of miR-122 and miR-192 in livers of mice fed with the
CDAA diet compared to control mice (Fig. 5G), strongly suggest that damaged or
stressed hepatocytes are a source of the increased circulating EVs and that
hepatocyte-specific microRNAs are released through EVs in circulation over time
during NAFLD progression. To evaluate whether these findings were related to
liver injury associated with NASH, and not to the CDAA model per se, we used a
second model of NAFLD by feeding mice with high fat (HF) diet for 12 weeks.
Histopathological and gene expression analyses revealed that mice fed with the HF
diet for 12 weeks developed NAFLD (Fig. 6A-6D). Importantly, as demonstrated
by the CDAA model, the levels of circulating EVs were significantly elevated with
HF feeding compared to chow (Fig. 6E). As shown in the CDAA model, the EVs
isolated from HF mice displayed markedly up-regulated levels of miR-122 and
miR-192 compared to EVs isolated from chow mice (Fig. 6F). Taken together
these data strongly support the concept that EVs are generated during NASH
development and are released in circulation potentially paving the way to the
development of a new generation of mechanism-based biomarkers for NASH.
Discussion
This study relates to the role of EVs as potential biomarkers of liver damage in
NAFLD. Results demonstrate that diet-induced NAFLD/NASH is associated with
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Figure 5. Identification of liver-related microRNAs encapsulated in EVs and released from liver during diet-induced NASH. (A) Expression levels of
miR-122 and –192 in EVs and (B) liver isolated from CDAA, CSAA and chow fed mice for 20 weeks. (C) Analysis of Liver carboxylesterase-PE/Calcein-
FITC positive circulating EVs isolated from CDAA and CSAA-fed mice for 20 weeks. (D) Western blot analysis of the hepatocyte-specific asialoglycoprotein-
receptor (ASGPR1) in purified EVs isolated from CSAA and CDAA-fed mice for 20 weeks. (E) Expression level of miR-122 encapsulated in EVs or
associated to Argonaute-2 (Ago2) in CSAA and CDAA-fed mice for 20 weeks. (F) Expression levels of miR-122 and –192 over time in circulating EVs and
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marked increased production and release of EVs in the liver and in circulation.
Detailed characterization of EVs identified both exosomes and microparticles
released into the bloodstream during experimental NASH. Circulating EVs were
enriched in miRNA-122 and miR-192 - two well-investigated and abundant
microRNAs in hepatocytes. Moreover, blood EV levels were dynamic, increasing
over time, becoming significantly higher as early as 8 weeks on the CDAA diet, a
time point that is associated with early NAFLD, and closely correlating with key
histopathological features of disease severity. A clustering analysis of the protein
profile of blood EVs allowed for differentiation of NAFLD animals versus
controls.
In light of the dramatic increase in the prevalence of NAFLD, and in
conjunction with the significant research effort in developing novel therapies
targeted to patients with NAFLD, dynamic and noninvasive biomarkers that can
be measured periodically to track disease changes in real time, are in great need.
Biomarkers would not only help in the diagnosis of NAFLD, but also be useful for
the assessment of treatment response and prognosis. We hypothesized that EVs -
membrane bound structures released from a variety of cell types during stress or
apoptosis and have been increasingly linked to cell-cell communication - have the
potential to fulfill these requirements. Two recent pilot studies in humans showed
increased levels of leucocyte-derived MPs in patients with NAFLD and in patients
with alcohol and/or chronic hepatitis C related cirrhosis supporting the concept
that EVs are potential biomarkers to monitor liver injury [20]. Unfortunately, EVs
derived from inflammatory cells are not specific and may be elevated in a number
of immune and inflammatory conditions associated with their activation thus
limiting their utility as biomarkers of liver disease [45–47]. Our data identify for
the first time the proteome of circulating EVs from NAFLD animals and
demonstrate that these vesicles carry a selective antigenic composition. Moreover,
hierarchical clustering analysis allowed for discrimination of mice with established
NASH from those with isolated steatosis, identifying for the first time a potential
signature in blood EVs that might be used to diagnose NAFLD noninvasively. We
further showed that blood EVs carry microRNAs and proteins (e.g. CES1)
abundant in liver, strongly suggesting the liver as an important source of these
EVs in circulation during NASH. Interestingly, we found a significant number of
proteins involved in cell death (Cathepsin D, Clusterin, CD5 antigen-like),
angiogenesis and cell-adhesion (Extracellular matrix protein 1, Desmoglein 1a/b,
SHC-transforming protein 1, Annexin A2, Fibronectin, Galectin-3-binding
protein, Vitronectin), antioxidant and redox signaling and inflammatory response
processes. The enrichment of these proteins in circulating EVs suggests that they
carry specific signatures, and materials, reflecting the pathological condition of the
organism of origin. The presence of oxidative stress and production of reactive
oxygen species (ROS) by dysfunctional mitochondria as a consequence of
(G) liver harvested from CDAA-fed mice for 4, 8 or 20 weeks or control mice. Mean values were normalized to U6 snRNA. Values represent mean¡ SD.
*P,0.05, **P,0.005, ***P,0.0005, Kruskal-Wallis test with post-hoc Mann-Whitney test and Bonferroni correction.
doi:10.1371/journal.pone.0113651.g005
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Figure 6. High fat diet induces liver steatosis and extracellular vesicles release in blood stream. (A) Liver specimens from wild type C57BL/6 mice
(n56) fed with the high fat diet (HF) or chow diet for 12 weeks, were used for assessing liver damage (Hematoxylin & eosin staining, H&E), fibrosis by
detecting the collagen deposition (Sirius red staining), cell death (TUNEL staining) and pathological angiogenesis (CD31 staining). (B) H&E liver specimens
were analyzed in a blinded way for steatosis, inflammation and ballooning and NAS score was determined in mice fed with HF diet for 12 wks or with control
diet.(C) Analysis of the expression of the transcripts for VEGF-A, FGF-b, CD126 (VE-cadherin), Collagen type-I, a-smooth muscle actin (a-SMA) and CTGF,
assessed by quantitative real-time PCR. The housekeeping gene 18S was used as internal control. (D) Plasma alanine aminotransferase (ALT) levels were
analyzed from mice fed with chow or high fat diet. (E) Whisker plot of flow cytometry analysis of circulating Calcein+ extracellular vesicles per mL of platelet-
free plasma isolated from high fat (HF, n56) or chow diet fed mice (n56) for 12 weeks. (F) Expression levels of miR-122 and –192 in circulating EVs. Values
represent mean ¡ SD. *P,0.05, **P,0.005, ***P,0.0005, Kruskal-Wallis test with post-hoc Mann-Whitney test and Bonferroni correction.
doi:10.1371/journal.pone.0113651.g006
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hepatocyte lipotoxicity during NAFLD progression [48], may explain the
significant presence of proteins involved in redox signaling pathways and
antioxidant enzymes. Importantly, we also detected a number of proteins
noteworthy for their involvement in cell death, such as proteins that have serine/
cysteine protease inhibitor domains [49]. We also identified the presence of a
large number of proteins involved in pathological angiogenesis, including proteins
responsible for cell motility, cell-cell adhesion, migration, sprouting and neovessel
formation [50]. The proteome of circulating EVs of CDAA-fed mice also reflects
the mechanisms of vesicle formation, as demonstrated by the presence of
glycolytic enzymes, cytoskeleton structural proteins and GTPases, which play a
role in the calcium-dependent or independent vesicle formation and trafficking
processes. The presence of atherogenic lipoproteins and scavenger receptors may
suggest a strong link between non-alcoholic steatohepatitis and cardiovascular
complications, as have been previously described [51].
Based on these results, we further examined the potential role of the circulating
extracellular vesicles, increased during NAFLD, for non-invasive monitoring of
disease progression. The levels of circulating extracellular vesicles isolated from
CDAA-fed mice for 4, 8 or 20 weeks were time-dependent, becoming significantly
higher at the 8 week time point and strongly correlated with the histopathological
features of NAFLD. In particular, the level of circulating EVs released during diet-
induced NAFLD strongly correlated with hepatic fibrosis, cell death and
pathological angiogenesis. Moreover, the circulating EVs from mice on the CDAA
diet were enriched in miR-122 and miR-192, two abundant microRNAs in
hepatocytes. The level of these microRNAs increased in EVs and decreased in
livers over time during NAFLD progression. The release of these microRNAs from
stressed or damaged hepatocytes in EVs during NAFLD progression may provide
an attractive explanation for the decreased expression level of miR-122 found in
the livers of patients with advanced NAFLD [44],as well as early stage hepato-
carcinogenesis from NASH in both an animal model and human tissue samples,
as recently reported [52]. Indeed, a recent study by Pirola et al [33] demonstrated
that, as opposed to healthy individuals where miR-122 is present in circulation
only in Ago2 complex fraction, in patients with NAFLD the majority of serum
miR-122 circulates in Ago2-free forms. The specific compartment was not further
assessed in this study and future studies to determine the circulating levels of miR-
122 in EVs from patients with fatty liver disease are warranted.
In order to validate the results observed in the CDAA model of NAFLD/NASH,
we studied a second murine model in which mice are fed a high caloric high fat
diet for a total of 12 weeks. The similar results obtained with this model strongly
suggest that the changes in blood EVs are related to NASH development and
exclude a potential confounding effect of the CDAA diet. Thus, our findings show
that EVs are produced and released during NAFLD progression, have a specific
antigenic composition reflecting the pathological alterations typical of its
progression and express microRNAs and proteins abundant in the liver.
Additionally, the EV levels are dynamic and change over time, correlating with
changes in liver histopathology characteristic of NAFLD/NASH. In conclusion,
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our study suggests that monitoring EVs in circulation may be a promising, novel,
non-invasive tool to assess disease progression in NAFLD, and uncover the
antigenic profile of these vesicles during experimental NAFLD development,
which are potential targets for immune-based diagnostics development.
Supporting Information
Figure S1. Extracellular vesicles purification by sucrose gradient. Extracellular
vesicles in platelet-free plasma (PFP) samples isolated from CDAA- or CSAA-fed
mice were purified by ultracentrifugation on a 10–70% sucrose-gradient to reduce
contaminants and soluble proteins. (A) and (B) show the PFP samples separation
after sucrose-gradient ultracentrifugation as detailed in Methods. (C) Silver
staining gel of different fractions obtained after sucrose-gradient ultracentrifu-
gation of PFP samples isolated from CDAA- and CSAA-fed mice for 20 weeks.
doi:10.1371/journal.pone.0113651.s001 (TIF)
Table S1. List of proteins in circulating extracellular vesicles isolated from
CSAA-fed mice based on LC-MS/MS analysis. Pure circulating extracellular
vesicles were isolated from CSAA (control diet)-fed mice for 20 weeks and
processed for proteomics analysis. Proteins are listed in the table with the
corresponding gene symbol and description based on GO Consortium, number of
peptides and percentage of coverage (% Cov). Proteomics data are representative
of three independent experiments.
doi:10.1371/journal.pone.0113651.s002 (DOCX)
Table S2. List of primers used for the gene expression studies.
doi:10.1371/journal.pone.0113651.s003 (DOCX)
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